'Pharmaceutical Contract Manufacturing Market Will Reach $47.6 Billion in 2012' Predicts Visiongain Report

Informations

• Publié par: visiongain
• Nombre de lectures: 18
• Langue: English

Extrait

'Pharmaceutical Contract Manufacturing Market Will Reach $47.6 Billion in 2012' Predicts Visiongain Report

PR Newswire LONDON, September 11, 2012

LONDON,September 11, 2012/PRNewswire/ -- A new report by visiongain predicts that the world market for pharmaceutical contract manufacturing will be worth$47.6 billionin 2012. Between 2011 and 2016, the overall market will grow with a compound annual growth rate (CAGR) of over 6%. Demand for outsourcing will increase worldwide, driving revenue growth. Those findings and others appear in Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022, published inAugust 2012. In 2011, active pharmaceutical ingredient (API) manufacturing services formed the largest market sector, accounting for more than two thirds of revenues. APIs will account for the majority of revenues throughout the coming 10 years. Increased demand for generic drugs will drive revenue growth for emerging- market contract manufacturing organisations (CMOs). Highly potent API (HPAPI) manufacturing will drive growth in the US andEurope. Increased outsourcing of finished dosage manufacturing will also stimulate developed-market growth. Development of biologics will increase demand for injectable dosage manufacturing services, including fill-finish and lyophilisation, the report also notes. Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Difficult economic conditions caused revenue to drop for many leading CMOs in recent years. Among the leading US and European market players, only a few achieved continuous revenue growth between 2009 and 2011. Many are now reporting an increased uptake of services, however. To remain competitive in the future, companies will need to react to trends in drug development. Companies investing in biologics manufacturing capacity will benefit from increased interest in this area." Visiongain's study forecasts the leading national pharmaceutical contract manufacturing markets in terms of demand. In 2011, the leading national market was the US, accounting for over 40% of demand for outsourced manufacturing. Much of this demand is met by CMOs in the US and EU. However, pharmaceutical companies will increasingly use CMOs inIndiaand Chinato supply APIs in the coming 10 years. Growth in national pharmaceutical markets in emerging countries will stimulate demand for outsourcing there. This demand will come from multinational companies seeking to enter the market, and domestic drug developers wanting to cut costs. The updated report provides quantitative and qualitative analysis of the contract manufacturing industry and market. It shows revenue forecasts for leading sectors and national markets and identifies future trends that will affect companies. The work also discusses 20 leading CMOs, including Catalent, Lonza and Patheon. Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022 adds to visiongain's portfolio of analytical reports covering pharmaceutical

outsourcing and services markets. Visiongain is a business information provider based inLondon, UK. For sample pages and further information concerning the Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 please visit: http://www.visiongain.com/Report/880/Pharmaceutical-Contract-Manufacturing- World-Market-Outlook-2012-2022 About visiongain Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based inLondon, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e- zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. Companies mentioned in the report include:

Abbott Contract Manufacturing (part of Abbott Laboratories) Abbott Laboratories ADVENTRX Pharmaceuticals Aenova (formerly Dragenopharm Apotheker Püschl and Swiss Caps) Aesica Pharmaceuticals Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil] Agennix Albany Molecular Research (AMRI) Alexion Pharmaceuticals Amgen Aptuit Athera Biotechnologies Avalanche Biotechnologies AVEO Pharmaceuticals Avesthagen BASF Ben Venue Laboratories (part of Boehringer Ingelheim) Bend Research Biogen Idec Blackstone Group Boehringer Ingelheim Bristol-Myers Squibb Cambridge Major Laboratories (CML) Cardinal Health Catalent Celltrion Centocor (now known as Janssen Biologics) CMIC CMO Cobra Biologics Holding Daiichi Sankyo Department of Pharmaceuticals [India] Divis Laboratories Dr. Reddy's Laboratories

DSM Sinochem Pharmaceuticals (DSP) Eclipse Therapeutics Elan Eli Lilly Emcure Pharmaceuticals Enobia Pharma (part of Alexion Pharmaceuticals) European Commission (EC) European Medicines Agency (EMA) Evonik Degussa (part of Evonik Industries) Evonik Industries Famar Fareva Farmhispania FDA Office of Combination Products (OCP) [US] Food and Drug Administration (FDA) [US] Frazier Healthcare Gallus BioPharmaceuticals GEA Lyophil Government Accountability Office (GAO) [US] GSK Halo Pharmaceuticals Haupt Pharma Hikal Hospira Hospira One 2 One (part of Hospira) Human Genome Sciences (part of GSK) Immune Pharmaceuticals Infa Group International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Jubilant HollisterStier (part of Jubilant Life Sciences) Jubilant Life Sciences Kemwell Biopharma Kensey Nash Korea Food and Drug Administration (KFDA) Lonza Marinopoulos Group Medicines and Healthcare Products Regulatory Agency (MHRA) [UK] Mesoblast Ministry of Health, Labor and Welfare (MHLW) [Japan] MorphoSys Nascent Biologics NextPharma Technologies Nipro NKT Therapeutics Novartis Nycomed (part of Takeda Pharmaceutical) Pantec Patheon Pfizer Pfizer CentreSource (part of Pfizer)

Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceuticals and Medical Devices Agency (PMDA) [Japan] Piramal Healthcare ProBioGen Procaps QRxPharma Quintiles R5 (part of Aesica Pharmaceuticals) Recepta Biopharma Recipharm RecipharmCobra Biologics (part of Cobra Biologics Holding) Roche Royal DSM SafeBridge Consultants Samsung Samsung BioLogics Sanofi SCM Pharma Seattle Genetics Sigmar Italia (part of Fareva) Silverfleet Capital Sinochem SkyePharma State Food and Drug Administration (SFDA) [China] Sun Capital Partners SurModics (part of Evonik Industries) Swedbank Teva Pharmaceutical Industries Therapeutic Goods Administration (TGA) [Australia] UCB Uquifa Vetter Pharma-Fertigung Vivante GMP Solutions (part of Lonza) Wasserburger Arzneimittelwerk (part of Recipharm) Wockhardt World Health Organization (WHO) Xencor

For an executive summary of this report or to order it today please contact: Email: Sara Peerun on [e-mail] Tel: [phone] Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to [e-mail] or call her on [phone]